Q-omics provides the consensus-scored CNBD1 profile across patient tissues and cancer cell-line models. CNBD1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CNBD1 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, CNBD1 RNA expression shows 6,593 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, HNSC, and STAD as cancer lineages where CNBD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNBD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNBD1 survival associations across molecular data types. CNBD1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNBD1 RNA expression–survival associations across cancer types. High CNBD1 expression shows unfavorable associations in KIRP, BLCA, ACC, COAD, KIRC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CNBD1 RNA expression.
This table summarizes CNBD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CNBD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNBD1 shows lower tumor expression in BRCA and COAD and higher tumor expression in HNSC, LUSC, LUAD and LIHC. The HNSC box plot shows higher CNBD1 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .001).
This table shows molecular features associated with CNBD1 in patient tissues and cancer cell lines. In patient samples, CNBD1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CNBD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
